Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study
Executive Summary
Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.